LONDON (Alliance News) - Scancell Holdings PLC Friday said that it will announce the results of phase one and two of its clinical trial in patients with stage three and four melanoma at the American Association for Cancer Research annual meeting in San Diego next Tuesday.
Scancell Holdings develops novel immunotherapies for the treatment of cancer.
Last month it said it had completed patient dosing with 8mg of SCIB1 ImmunoBody in part one of its on-going phase 1/2 clinical trial in patients with Stage III/IV melanoma. The trial followed a study the firm conducted which showed that a 4mg dose of SCIB1 produced an immune response that might be associated with clinical benefit in patients with malignant melanoma, regulatory approval was granted for a higher dose of 8mg.
Scancell said the data will be presented at the upcoming American Association for Cancer Research annual meeting in San Diego, California, on April 8.
The meeting is a cancer research event with about 18,000 researchers, patient advocates, and other professionals in the cancer field.
Scancell shares were trading 1.9% or 0.60 pence higher Friday morning at 33.10 pence per share.
By Rowena Harris-Doughty; rowenaharrisdoughty@alliancenews.com; @rharrisdoughty
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)